Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC

Hao Wang, MS1,2, Ying Huang, MS2, Hua Chen, MS2, Yan Shao, MS2, Yanhua Duan, MS2, Aihui Feng, MS2, Hengle Gu, MS2, Xiurui Ma, MS3, Zhiyong Xu, PhD2, Qing Kong, PhD1, and Yongkang Zhou, MS3

Abstract

Background/purpose: To access the comparative dosimetric and radiobiological advantages of two methods of intensity-modulated radiation therapy (IMRT)-based hybrid radiotherapy planning for stage III nonsmall cell lung cancer (NSCLC). Methods: Two hybrid planning methods were respectively characterized by conventional fraction radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT) and CFRT and simultaneous integrated boost (SIB) planning. All plans were retrospectively completed using the 2 methods for 20 patients with stage III NSCLC. CFRT and SBRT dose regimes 2 Gy \times 30 f and 12.5 Gy \times 4 f were, respectively, used for planning target volume of lymph node (PTVLN) and planning target volume of the primary tumor (PTVPT), while dose regimes 2 Gy \times 26 f for PTVLN and sequential 2 Gy \times 4 f for PTVLN combined with 12.5 Gy \times 4 f for PTVPT were adopted for CFRT and SIB plans. SBRT and SIB EQD2 dose were calculated voxel by voxel, and then, respectively, superimposed with 30-fraction and 26-fraction CFRT plan dose to achieve biological equivalent dose (BED) dosimetric parameters of CFRT and SBRT and CFRT and SIB plans. Tumor control probability (TCP)/normal tissue complication probability (NTCP) was, respectively, calculated by equivalent uniform dose/Lyman–Kutcher–Burman models. BED plan parameters and TCP/NTCP were analyzed between 2 methods of hybrid planning. Primary tumor/lymph node (LN)/total TCP values were, respectively, evaluated as a function of the radiation dose needed to control 50% of tumor (TCD50) for 20 patients. Dosimetric errors were analyzed by non-transit electronic portal imaging device dosimetry measurement during hybrid plan delivery. Results: Statistically lower BED plan parameters of PTVLN D2 and homogeneity index resulted in slightly lower averaged LN/total TCP curves by CFRT and SIB planning. The gaps between Max and Min LN/total TCP curves were significantly closer for CFRT and SIB planning, which indicated better robustness of LN/total TCPs. A lower esophagus dose resulted in a lower esophagus NTCP by CFRT and SIB planning, which may be compromised by 1 week shorter overall treatment time by CFRT and SIB irradiation. Spinal cord Dmax was significantly reduced by CFRT and SIB plans. The dose verification results of the subplans involved in hybrid plans were acceptable, which showed that the 2 methods of hybrid planning could be delivered accurately in our center. Conclusion: CFRT and SIB plannings have more advantages on BED plan parameters and TCP/NTCP than CFRT and SBRT planning, and both methods of IMRT-based hybrid planning could be executed accurately for stage III NSCLC. The effectiveness of the results needs to be validated in the hybrid trial.

Keywords

Stage III NSCLC, hybrid planning, BED plan parameters, TCP/NTCP

1 Institute of Modern Physics, Fudan University, Shanghai, China
2 Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
3 Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China

Corresponding Author:
Yongkang Zhou, Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Email: zhou.yongkang@zs-hospital.sh.cn

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Background

For unresectable stage III nonsmall cell lung cancer (NSCLC), primary tumor (PT) and regional lymph nodes (LNs) both had a recurrence possibility according to several evidential trials by definitive concurrent chemoradiotherapy (CCRT).\(^1\)–\(^3\) while conventional fraction radiotherapy (CFRT) was used. A reasonable and effective treatment for stage III NSCLC could be CFRT combined with stereotactic body radiotherapy (SBRT) boost. One important strategy is to use CFRT for PT and LNs followed by SBRT for residual PT and LNs disease.\(^4\)–\(^7\) This requires us to face another challenge that dose escalation to the mediastinal region (eg, esophagus and heart) in both CFRT as SBRT\(^8\)–\(^11\) may have a risk to increase the possibility of severe toxicity events, such as esophageal and cardiac radiation injury and finally a negative impact on overall survival.\(^8\)–\(^12\),\(^13\)

From the results of two studies on the pattern of locoregional failure,\(^14\),\(^15\) it was observed that PT recurrences occurred more often than lymph node (LN) recurrences. Based on these evidential trials, we are more confident that appropriate hybrid radiotherapy should include SBRT to PT followed by image-guided adaptive CFRT to LNs (called CFRT & SBRT). The result of a recent clinical trial\(^16\) using CFRT & SBRT planning showed that irradiation up to \(\geq 100\) Gy of biological equivalent dose (BED) (target \(\alpha/\beta = 10\)) achieved a 76% crude local control rate (LCR) during a 2-year follow-up survey for stage III lung cancer while the overall treatment time (OTT) \(\leq 60\) days was allowed.

For CFRT & SBRT planning, the conformity index of target dose coverage is affected by the interaction effect of the two components of hybrid planning, and it would be more significant when the distance between PT and LNs is closer. To relieve the interaction effect, an alternative option was proposed by Peulen et al\(^17\) that simultaneous integrated boost (SIB) was used to irradiate both PT and LNs, and then LNs were treated by the rest fractions of CFRT (called CFRT & SIB).

Two possible options may be challenging for not only the uncertainty of the interaction effect from two subplans of different hybrid methods but also the differences in linac parameters settings in the optimization process.

For linac parameters settings, compared to the jaw auto-chosen method applied for intensity-modulated radiation therapy (IMRT)-based CFRT & SBRT planning, which were, respectively, optimized, the fixed jaw method was inevitably adopted in IMRT-based SIB components of CFRT & SIB planning, which was optimized in a single process. Fields jaws of SIB plans were, respectively, adaptive to PT and LNs disease, and the fixed jaw method needs to be used to reduce the delivery of PT and LNs beams to LNs and PT in a single optimization process.

The differences in the interaction effect and linac parameters settings may result in the difference in the physical and BED plan parameters, and BED is an established measure for quantifying the expected biological effect of different radiation dose fractionation schedules.\(^18\)–\(^20\) The difference may further lead to the difference in radiobiological response, including tumor control probability (TCP) and normal tissue complication probability (NTCP).\(^21\)–\(^23\) A question emerges concerning which hybrid planning technology is better with regard to tumor irradiation and organs at risk (OARs) safety.

Another concern is that TCPs of PT and LNs treated by different dose regimes differ from each other. Yeon et al\(^16\) reported that for stage III lung cancer, all in-field recurrences/out-field regional recurrences arise in the locations of LNs disease treated by CFRT plans, not in lung fields treated by SBRT plans. The result was consistent with a basic principle implied in the TCP model\(^24\),\(^25\) that in the context of meeting dose constraints of OARs, different types of tumors receiving different dose regimes would have different TCPs, and a higher EQD\(_2\) dose would result in a higher TCP. TCP value was also featured by the parameter of radiation dose needed to control 50% of tumor (TCD\(_{50}\))\(^26\),\(^27\) and different TCD\(_{50}\) ranging from 50 to 80 Gy were observed for lung cancer patients from several previous studies.\(^27\),\(^28\)

The main problem that we are facing to evaluate the LCR of stage III NSCLC patients treated by hybrid radiotherapy is that the individual TCP value is determined by the hybrid planning method, dose regime, and TCD\(_{50}\). The hybrid planning method and TCD\(_{50}\)-specific TCP values with a certain dose regime would be analyzed in this work. It could fully evaluate PT/LNs total TCP values as a function of TCD\(_{50}\) for 20 stage III NSCLC patients treated by both methods of hybrid planning. For the simulation of TCP values, the equivalent uniform dose (EUD) model has been chosen.\(^24\),\(^25\) EUD is the homogeneous dose inside an organ that has the same clinical effect as a given, arbitrary dose distribution.\(^29\)
Hybrid planning involves various optimization steps, which results in hybrid plans, especially SIB plans are highly modulated radiotherapy plans. Dosimetric errors between the planned and the delivered dose may result from the uncertainties in beam data measurement/modeling and/or radiation plan delivery of the highly modulated plans. The delivery accuracy of hybrid plans determines the feasibility of IMRT-based hybrid planning in the treatment of stage III NSCLC.

The comparative advantages of two methods of IMRT-based hybrid planning were evaluated in this work. BED plan parameters and TCP/NTCP were analyzed between two methods of hybrid radiotherapy planning for 20 stage III NSCLC patients. The hybrid planning method and $TCD_{50}$-specific PT/LNs/total TCP values were evaluated for 20 NSCLC patients. Dosimetric errors by nontransit electronic portal imaging device (EPID) measurement were checked to evaluate the feasibility of IMRT-based hybrid planning.

### Materials and Methods

#### Patient Selection

Twenty patients with stage III NSCLC were retrospectively enrolled in this hybrid planning study from February 2015 to August 2019 (Table 1). We have obtained informed consent from the study participants or their families in a verbal version; they agreed that all treatment data of patients could be used in this study. The patients need to meet the conditions, including PT volume ≤ 15 cc, and the separation distance between PT and LNs disease ≥5 cm. In the 3D domain, the separation distance between PT and LNs disease was measured on a 1-slice computed tomography (CT) image when PT and LNs spatially separated on the same slice, otherwise, the separation distance was calculated by the root mean square of the spacing distance in three-dimensional direction (superior inferior, anterior posterior, left right directions).

#### CFRT and SBRT Planning

All CFRT and SBRT plannings (C & S plannings) formed were retrospectively made on AIP-CT by an experienced physicist. The C & S planning method is shown in Figure 1. Dose regime 2 Gy × 30 f was used for the CFRT plan, while dose regime 12.5 Gy × 4 f was adopted for all SBRT plans for a fair comparison in this study. EDGE Linac (Varian) was used for hybrid planning in a Pinnacle 9.10 planning system.

Five to eight step-and-shoot IMRT fields using a 6 MV X-ray were adopted in all CFRT plans for $PTV_{LN}$, and the method has been shown in our previous work. The direct machine parameter optimization algorithm was used for CFRT plans optimization and Collapsed Cone Convolution Superposition algorithm was adopted for dose calculation with a 2.5 mm dose grid. The centroid of $PTV_{LN}$ was set as the isocenter of the IMRT fields, and appropriate delivery directions were used for CFRT fields for irradiation reduction to $PTV_{PT}$.

Nine to 11 coplanar single-segment IMRT fields were used for the $PTV_{PT}$ SBRT boost plan which was different from three-dimensional conformal radiation therapy planning with 8 to 12 noncoplanar fields, and the method was proposed in our another study. To increase the robustness of possible interplay effects that are known from highly modulated IMRT irradiations and high-dose rates in relation to moving targets, each IMRT field with a single modulated segment was produced in an optimization process. The minimum projection size of the $PTV_{PT}$ from all beams’ eye views was set as the minimum size of segment aperture to achieve sufficient dose coverage of the moving target and a steeper dose drop gradient.

#### Treatment Preparation

Four-dimensional planning CT was acquired for each patient including the entire lung. Nine respiratory phases CT images with 3-mm thickness were, respectively, reconstructed by a Siemens CT scanner SOMATOM Definition AS (Siemens Medical Systems) and then exported to MIM Maestro 6.6.5 (MIM Software). Maximum intensity projection CT (MIP-CT) and average intensity projection CT (AIP-CT) were, respectively, reconstructed.

lymphonodus of clinical target volume ($CTV_{LN}$) was contoured on AIP-CT with mediastinal window-level, which was registered with diagnostic fluorodeoxyglucose positron emission tomography (PET)/CT. The planning target volume of the lymph node ($PTV_{LN}$) was 8 mm uniformly expanded from $CTV_{LN}$. Int target volume (ITV) was contoured on MIP-CT with lung window-level, and then $PTV_{PT}$ was 5 mm uniformly expanded from ITV. PTV margin was appropriately adjusted by the actual tumor motion. A second dedicated radiation oncologist with at least 5 years of experience checked all contours.

### Table 1. Patient Characteristics

| Factors            | Values       |
|--------------------|--------------|
| Sex                | Male 18      |
|                    | Female 2     |
| Age (years)        | Median (range) 62 (46-71) |
| Location (lobe)    | Right upper 10 |
|                    | Right middle 1 |
|                    | Right lower 5 |
|                    | Left upper 2  |
|                    | Left lower 2  |
| Clinical stage     | IIA 9        |
|                    | IIB 11       |
| Radiotherapy sequence | CFRT before SBRT boost 3 |
|                    | CFRT after SBRT boost 17 |
| $PTV_{PT}$ volume (cc) | Median (range) 30.7 (10.9-100.1) |
| $PTV_{LN}$ volume (cc) | Median (range) 199.5 (24.8-452.3) |

Abbreviations: CFRT, conventional fraction radiotherapy; SBRT, stereotactic body radiotherapy; $PTV_{PT}$, planning target volume of the primary tumor; $PTV_{LN}$, planning target volume of the lymph node.
centroid of PTV<sub>PT</sub> was set as the isocenter of SBRT fields, and appropriate delivery directions were also used for SBRT fields for irradiation reduction to PTV<sub>LN</sub>. EQD<sub>2</sub> prescription dose actually needed for PTV<sub>PT</sub> was achieved by the reduction of PTV<sub>PT</sub> unintended dose (D<sub>99</sub>) from the CFRT plan, and then the actual fraction dose of SBRT was downscaled by the actually needed EQD<sub>2</sub> dose of PTV<sub>PT</sub>.

**CFRT and SIB Planning**

All CFRT and SIB plannings (C & S IBI plannings) formed were also retrospectively made on AIP-CT by the same experienced physicist, and the flowchart of C & S IBI planning is shown in Figure 2. Dose regime 2 Gy × 26 f was used for CFRT plans, while sequential dose regime 2 Gy × 4 f to LNs with 12.5 Gy × 4 f to PT was adopted for all SIB plans. Twenty-six fractions of CFRT plans were downscaled from 30 fractions CFRT plans of C & S hybrid plans. Beam numbers and directions of IMRT-based SIB plans were set as the same as the total beams used in CFRT and SBRT plans for C & S hybrid planning. SIB beams with appropriate delivery directions were, respectively, used for irradiation to PTV<sub>PT</sub> and PTV<sub>LN</sub>. The fixed jaw method was used for IMRT beams, respectively, for PT and LNs disease to restrict dose delivery to LNs and PT. EQD<sub>2</sub> prescription dose actually needed for PTV<sub>PT</sub> was also achieved by the reduction of PTV<sub>PT</sub> unintended dose (D<sub>99</sub>) from 26 fractions CFRT plans, and then the actual fraction dose for PTV<sub>PT</sub> was downscaled by actually needed EQD<sub>2</sub> dose of PTV<sub>PT</sub>.

Figure 1. Flowchart of conventional fraction radiotherapy & stereotactic body radiotherapy (C & S) hybrid planning.
**BED Plan Parameters**

As a voxel dose of more than 8 Gy needed to be EQD2 corrected in 4-fraction SBRT and SIB plans, an auxiliary contour structure called Ring8Gy (each voxel dose within Ring8Gy was more than 8 Gy) was, respectively, created for SBRT and SIB plans. Voxel-level EQD2 dose within ITV and OARs covered by Ring8Gy was calculated by Equation (1) \[ \text{EQD2 dose} = \frac{D \times (d + \alpha/\beta)}{2 + \alpha/\beta} \] where \( D \) is the voxel total dose (Gy); \( d \) is the voxel fraction dose (Gy), and the fraction number is 4.

BED plan parameters included: PTV\textsubscript{PT} D\textsubscript{2}, homogeneity index (HI), and CI\textsubscript{140Gy}; PTV\textsubscript{LN} D\textsubscript{2}, HI, and CI\textsubscript{60Gy}; total lung mean dose (MLD), \( V_5 \), and \( V_{20} \); esophagus \( D_{\text{max}} \), \( V_{35} \), and \( V_{50} \); heart mean dose (MHD), \( D_{\text{max}} \), \( D_{30} \), and \( D_5 \); spinal cord \( D_{\text{max}} \).

CI\textsubscript{140Gy} indicated the conformity index of PTV\textsubscript{PT} covered by BED 140 Gy, which was estimated from the BED level at the border of PTV\textsubscript{PT} with about 50 Gy physical dose using equation (1) and lung \( \alpha/\beta \) value 3.

Figure 2. Flowchart of conventional fraction radiotherapy & simultaneous integrated boost (C & SIB) hybrid planning.

---

\[ \text{EQD2 dose} = \frac{D \times (d + \alpha/\beta)}{2 + \alpha/\beta} \]
TCP/NTCP Parameters

To assess the clinical response difference between 2 kinds of hybrid plans, PT TCP (TCPPT); LNs TCP (TCPLN); total lung, esophagus, heart, and spinal cord NTCPs were, respectively, calculated using an in-house Matlab script. As tumor control events of PT and LNs were taken as 2 independent events in this work, total TCP (TCPtotal) was taken as the product of TCPPT and TCPLN, and the EUD model was used for TCP calculation using the equations as follows22,24–26:

\[
\text{EUD} = \left[ \sum_{i=1}^{n} (v_iD_i^n) \right]^{1/\alpha}
\]

(2)

\[
\text{TCP} = \frac{1}{1 + (\text{TCD}_{50}/\text{EUD})^{\gamma_{50}}}
\]

(3)

where TCD50 means the uniform dose that was needed to control 50% of the tumor, \(\gamma_{50}\) means the TCP variation due to a 1% change of TCD50, and \(D_i\) means a uniform dose of partial volume \(v_i\), TCD50, \(\gamma_{50}\), and \(\alpha\) were, respectively, set as 51.24 Gy, 0.83, and 0.30 for TCP calculation.35

Lyman–Kutcher–Burman model was adopted for NTCP calculation using the equations as follows36.

\[
\text{NTCP} = \frac{1}{\sqrt{2\pi}} \int_{-\infty}^{\tau} e^{-x^2/2} dx
\]

(4)

\[
t = \frac{\text{D}_{\text{eff}} - \text{TCD}_{50}}{m\text{TCD}_{50}}
\]

(5)

\[
\text{D}_{\text{eff}} = \left( \sum_{i} v_iD_i^{1/n} \right)^n
\]

(6)

where TD50, \(n\), and \(m\) were, respectively, set as 29.9 Gy, 1, and 0.41 for pneumonia from Semenko’s results37; TD50, \(n\), and \(m\) were, respectively, set as 50.6 Gy, 0.64, and 0.13 for pericarditis from Martel’s results38; TD50, \(n\), and \(m\) were, respectively, set as 51 Gy, 0.44, and 0.32 for esophagitis from Chapet’s results39; TD50, \(n\), and \(m\) were, respectively, set as 66.5 Gy, 0.05, and 0.175 for myelitis from Luo et al’s results.40

Hybrid planning method/TCD50-specific TCPs

The LCR of cancer patients in a certain follow-up period depends on the individual tumor control possibility (TCP), and the TCP value is a hybrid planning method/TCD50 specific in hybrid radiotherapy for stage III NSCLC. In this work, PT and LNs TCP values of 20 patients with stage III NSCLC were, respectively, calculated to fully simulate LCR by involving different TCD50 and methods of hybrid planning. Equations (2) and (3) were used to calculate the TCP value. For each patient, PT and LNs TCPs were, respectively, calculated as a function of TCD50 ranging from 50 to 80 Gy at 1 Gy interval using an in-house Matlab script, and then the total TCP was obtained as the product of PT TCP and LNs TCP. Maximum, minimum, and averaged PT/LNs/total TCPs were, respectively, achieved from the TCP values of 20 patients with a certain TCD50 value ranging from 50 to 80 Gy at 1 Gy interval for 2 methods of hybrid planning. The hybrid planning method/TCD50-specific TCPs were achieved to assess the PT/LNs/total TCPs of 20 NSCLC patients.

Delivery Accuracy of Hybrid Planning

The accuracy of hybrid plan delivery of 20 patients was, respectively, verified by a nontransit EPID dosimetry system (Varian). A gamma analysis was used for the comparison of planned and delivery dose distributions with a 5% dose threshold and a 2%/2 mm global gamma criterion for CFRT and SBRT plans, while a 2% dose threshold and a 2%/2 mm global gamma criterion for SIB plans. The delivery accuracy of hybrid plan components (CFRT, SBRT, and SIB) was acceptable in our center when the passing rates reached more than 90% using the above criteria. In this work, the verification results of hybrid plan components were analyzed, including that (1) \(\gamma_{\text{mean}} < 1\) meant the gamma value passing rate; (2) \(\gamma_{\text{mean}}\) indicated the mean gamma value of all measured points; (3) % (area dose diff <3%) meant the area percentage relative to the whole region of interest where dose difference between measured and planned dose was <3%; and (4) \(\Delta D_{\text{true}}\%\) indicated the isocenter dose difference between planned and delivered doses.

Data Analysis

BED plan parameters and TCP/NTCP were analyzed by a paired-samples t-test between 2 methods of hybrid planning using SPSS 20.0 statistical software (IBM Corporation), and it was considered statistically when \(p\)-value < .05.

Results

BED Plan Parameters Comparison

For 20 patients’ hybrid plans, target coverage (PTVPT: \(V_{100\%}\geq95\%\), PTVLN: \(V_{90\%}\geq99\%\)) and OARs constraints were all met. BED isodose lines of 2 methods of hybrid planning were shown for 1 patient in Figure 3. Compared to C & S planning, PTVLN achieved a higher dose conformity, spinal cord and esophagus got more sparing for the patient from C & SIB planning.

Figure 4 shows the BED-based dose-volume histograms (DVHs) of 2 methods of hybrid planning. The solid lines are indicated as averaged DVHs over a total of 20 patients for PTVPT (red curve), PTVLN (orange curve), total lung (blue curve), heart (magenta curve), esophagus (black curve), and spinal cord (green curve). The dashed lines show the upper and lower limits of the DVHs. In Figure 4, it could be seen that C & SIB plans are close to each other with respect to irradiation of PTVLN, while \(D_2\) values of PTVLN from C & SIB plans were statistically lower than the ones from C & S plans.
The esophagus DVHs have a larger deviation due to the difference in anatomical morphology over a total of 20 patients.

The averaged BED plan parameters of 20 patients are, respectively, shown for 2 kinds of hybrid plans in Table 2. The results are shown as mean values and standard deviations. Irradiation of 95% volume of PT resulted in comparable BED values close to 140 Gy, while the BED value of LNs disease was close to 60 Gy. C & SIB hybrid planning provided lower irradiation levels of the esophagus (V_{50} and D_{max}) and spinal cord (D_{max}) compared to C & S planning, while a lower-dose hotspot (D_{2}) was observed in PTV_{LN} from C & SIB planning.

TCP/NTCP Comparison

In Table 3, the TCP/NTCP results demonstrate that both methods of hybrid planning are effective techniques for irradiation of stage III NSCLC. Most of the TCP/NTCP results were equivalent between the 2 methods of hybrid plans, while C & SIB planning provided lower esophagus NTCP (43.2 ± 22.4%) compared to C & S planning (45.8 ± 23.6%).

Hybrid Planning and TCD_{50}-Specific TCPs

The averaged results of PT/LNs/total TCP values and their Max/Min limits are shown in Figure 5 as a function of TCD_{50} for 2 methods of hybrid planning. According to Mehta et al\textsuperscript{27} and Wulf et al\textsuperscript{28} the TCD_{50} values probably lie in a range from 50 to 80 Gy. In this case, averaged TCP curves show that C & S and C & SIB planning should have almost equivalent efficiency. In general, C & S plans to allow irradiation of the PT and LNs to a higher dose than C & SIB plans, and it is observed that averaged PT/LNs/total TCP curves as a function of TCD_{50} are slightly higher for C & S planning in Figure 5(a) to (c). Meanwhile, Figure 5 shows that the gaps between Max and Min limits of LNs/total TCP curves are closer for C & SIB planning, which may indicate that the robustness of LNs/total TCPs achieved by C & SIB planning would be better.

The hybrid planning method/TCD_{50}-specific LNs/PT/total TCPs are, respectively, shown in Figure 6(a) to (c) for 20 NSCLC patients. PT/LNs/total TCPs decrease (green→red) with a higher TCD_{50} ranging from 50 to 80 Gy for 2 methods of hybrid planning. Total TCPs are mainly determined by lower LNs TCPs (ranging from 30% to 79%) which are
irradiated by CFRT, compared to PT with TCP values of more than 91%, which are irradiated by SBRT.

**Delivery Accuracy of Hybrid Plans Components**

Table 4 summarizes portal dosimetry results of the hybrid plan components (SBRT, CFRT, and SIB plans). Mean results and ranges of 20 patients were given, including passing rates (% $\gamma < 1$), mean $\gamma$ value ($\gamma_{mean}$), the area percentage of dose difference <3% (% [area dose diff <3%]), and dose difference at isocenter ($\Delta D_{isoc}$ [%]).

The average passing rates of SBRT and CFRT plans were around 97%, while SIB plans reached about 99% using the 2%/2 mm criterion. The delivery errors of hybrid plan
components were acceptable in our center when the passing rates were more than 90%. The $\gamma_{\text{mean}}$ of all plans was no more than 0.46 which indicated great consistency between planned and measured doses. Figure 7 shows an example of composite dose difference. Average percentage (area dose diff <3%) of SBRT and CFRT plans were, respectively, 74.4% and 78.7%, while SIB plans reached about 94.5%. The measured dose at the isocenter of the hybrid plans showed about 2% systematically lower than the planned dose.

**Discussion**

Two methods of IMRT-based hybrid planning were used in the dosimetric and radiobiological study of stage III NSCLC. BED plan parameters and TCP/NTCP showed that 2 methods of hybrid planning were feasible and did not compromise OARs’ dose constraints. For a fair comparison, dose regime $4 \times 12.5\text{Gy}$ was given to PT for all hybrid plans in this hybrid planning study. Lower $D_2$ and HI of PTV$_{LN}$ resulted in slightly lower averaged LNs/total TCP curves for C & SIB planning. Closer Max/Min LNs and total TCP curves indicated better robustness of LNs and total TCPs for C & SIB planning. C & SIB planning could spare the esophagus and spinal cord more in BED dosimetry, and a lower esophagus NTCP could be achieved by C & SIB planning. The Hybrid planning method/TCD$_{50}$-specific TCPs were also evaluated for 20 stage III NSCLC patients. The dose verification results of the subplans involved in the 2 kinds of hybrid plans were very good, which showed that 2 methods of hybrid planning could be delivered accurately in our center.

As the nodal area always is involved in most regional recurrences for stage III NSCLC treated by CFRT,$^{15,16}$ it is important to reduce the risk of LN recurrence. The tolerance of CCRT followed by a sequential SBRT boost in stage III NSCLC has been reported by several studies.$^{4-7}$ BED $\geq$100 Gy has been adopted by all these studies to obtain a high LCR. Most of these studies applied a dose escalation to both PT and LNs residual disease,$^{4-7}$ while grade 5 bronchopulmonary hemorrhage and

---

**Table 2.** BED Plan Parameters Comparison Between Two Methods of Hybrid Planning

| Parameter | C & S | C & SIB | $P$-value |
|-----------|------|--------|-----------|
| $\alpha/\beta$ | 10 | 10 | |
| $D_2$ | 204.4 ± 8.0 | 204.7 ± 10.4 | .891 |
| HI | 1.40 ± 0.08 | 1.41 ± 0.07 | .880 |
| CI$_{140\text{Gy}}$ | 0.77 ± 0.10 | 0.80 ± 0.10 | .208 |
| $D_2$ | 74.8 ± 10.6 | 69.8 ± 3.7 | .038 |
| HI | 1.20 ± 0.14 | 1.14 ± 0.05 | .055 |
| CI$_{60\text{Gy}}$ | 0.38 ± 0.13 | 0.37 ± 0.13 | .193 |
| Total lung | 3 | 3 | |
| $V_5$ | 46.0 ± 11.2 | 44.6 ± 11.7 | .260 |
| $V_{20}$ | 25.4 ± 7.9 | 24.1 ± 5.7 | .333 |
| MLD | 15.7 ± 3.1 | 15.4 ± 3.1 | .280 |
| Heart | 3 | 3 | |
| $D_5$ | 38.5 ± 22.7 | 37.6 ± 22.5 | .365 |
| $D_{30}$ | 12.2 ± 12.7 | 11.8 ± 12.6 | .284 |
| $D_{\text{max}}$ | 6.67 ± 17.1 | 63.5 ± 21.6 | .466 |
| MHD | 10.7 ± 7.6 | 10.5 ± 7.6 | .408 |
| Esophagus | 10 | 10 | |
| $V_{35}$ | 66.3 ± 22.8 | 61.7 ± 23.9 | .238 |
| $V_{50}$ | 52.1 ± 27.4 | 49.6 ± 27.9 | .026 |
| $D_{\text{max}}$ | 68.8 ± 6.9 | 66.3 ± 5.7 | .039 |
| Spinal cord | 2 | 2 | |
| $D_{\text{max}}$ | 46.6 ± 5.4 | 45.0 ± 5.3 | .027 |

**Table 3.** TCP/NTCP Comparisons Between Two Methods of Hybrid Planning

| Parameters | C & S (mean ± Std) | C & SIB (mean ± Std) | $P$-value |
|------------|--------------------|----------------------|-----------|
| TCP$_{LN}$ | 68.6 ± 3.1% | 68.4 ± 2.1% | .719 |
| TCP$_{PT}$ | 98.1 ± 0.3% | 98.0 ± 0.2% | .395 |
| TCP$_{total}$ | 67.3 ± 3.1% | 67.1 ± 2.0% | .670 |
| NTCP$_{total\text{lung}}$ | 9.1 ± 4.4% | 9.3 ± 5.2% | .583 |
| NTCP$_{heart}$ | 0.000 ± 0.006% | 0.000 ± 0.01% | .291 |
| NTCP$_{eso}$ | 45.8 ± 23.6% | 43.2 ± 22.4% | .034 |
| NTCP$_{spinal\text{cord}}$ | 1.1 ± 0.7% | 0.9 ± 0.6% | .086 |

**Abbreviations:** BED, biological equivalent dose; SIB, simultaneous integrated boost; PTV$_{PT}$, planning target volume of the primary tumor; PTV$_{LN}$, planning target volume of lymph node; MHD, heart mean dose; MLD, lung mean dose.

Bold values in Table 2 indicate that the groups of data have statistical difference.

**Abbreviations:** TCP, tumor control probability; NTCP, normal tissue complication probability; SIB, simultaneous integrated boost; LN, lymph node; PT, primary tumor; CFRT, conventional fraction radiotherapy; SBRT, stereotactic body radiotherapy; C & S, CFRT and SBRT; C & SIB, CFRT and SIB; TCP$_{LN}$, LNs TCP; TCP$_{total}$, total TCP.

Bold values in Table 3 indicate that the groups of data have statistical difference.
a tracheoesophageal fistula were consequently observed.\textsuperscript{5,6} The Radiation Therapy Oncology Group (RTOG) 0617 trial, which analyzed the treatment response difference between groups that received a total dose of 74 and 60 Gy by 2 Gy per fraction, found that 2-year local recurrence free survival and overall survival rates did not increase with a higher total dose.\textsuperscript{8} This justifies an appropriate dose regime for LNs combined with an SBRT dose escalation only to the PT, thus high BED irradiation to mediastinal organs (eg, heart and esophagus) is avoided, which often reduces the risk of cardiac and esophageal toxic events in both CFRT as SBRT\textsuperscript{8–11} and possibly reduces an adverse effect on overall survival rates.\textsuperscript{8,12,13}

In this work, we chose 2 methods of hybrid planning with dose escalation only to PT. C & S hybrid planning has simple steps, but it may lead to obvious interaction effects when the lung lesions are close to the LNs disease. C & SIB hybrid planning is relatively more complex, but the SIB plan component may reduce the total interaction effect to a certain extent. Due to the differences in the methods between the 2 hybrid plans, it may cause differences in BED plan parameters, and may further result in clinical response differences for stage III NSCLC.

There have been few studies to compare 2 kinds of recently widely used hybrid plans for stage III NSCLC to our knowledge. On account of the assumption that the proper BED calculation model\textsuperscript{33} and target & OARs’ $\alpha/\beta$ values\textsuperscript{34} have been used for the results of SBRT and SIB plans, it is the first research to evaluate the comparative advantages of two methods of IMRT-based hybrid planning based on BED plan parameters and TCP/NTCP. In general, the question arises whether the

Figure 5. The averaged dependence (solid line) of LNs TCP (a), PT TCP (b), and total TCP (c) on TCD\textsubscript{50} for C & S planning (brown line) and C & SIB planning (green line). Dashed lines show the lower and upper limits.

Abbreviations: LN, lymph node; PT, primary tumor; SIB, simultaneous integrated boost; TCD\textsubscript{50}, radiation dose needed to control 50\% of tumor; TCP, tumor control probability;
**Figure 6.** LNs TCPs (a), PT TCPs (b), and total TCPs (c) were plotted in (a, b, and c) as a function of TCD50 ranging from 50 to 80 Gy at 1 Gy interval for 20 NSCLC patients. First/second 20 patients’ TCPs were, respectively, achieved from C & S and C & SIB planning.

Abbreviations: LN, lymph node; NSCLC, nonsmall cell lung cancer; PT, primary tumor; TCD50, radiation dose needed to control 50% of tumor; TCP, tumor control probability.
comparison of the 2 hybrid plans is at all justified by the uncertainty of the planning evaluation due to unsafe α/β assumptions. From our previous work, it could be seen that there were at least moderate correlations between physical and BED plan parameters if the same BED calculated model and α/β assumptions were used for 2 methods of hybrid planning. Under the same conditions, the results of the comparison between the 2 hybrid plans still seem to be credible in this work.

As the presence of the difference between 2 time-point planning CTs and related anatomical morphology, the sum of hybrid plans was even more difficult, especially for the 3 patients treated by CFRT with a sequential SBRT boost. All hybrid plans were retrospectively completed on first planning 4D-CT due to the reason that we tried to compare BED plan parameters and TCP/NTCP of 2 hybrid plans, while the differences in anatomical structure between the 2 planning CTs were neglected in this study.

The interplay effect in relation to moving targets still needed to be considered to improve the robustness of dose distribution, and 2 kinds of IMRT-based hybrid planning were proposed in this work. Jens et al reported that robust treatment sequences correlated with human breathing patterns could be produced by iteratively reducing the maximum allowed dose rate with the application of fast IMRT/volumetric modulated arc therapy (VMAT) delivery techniques. Damodar et al reported a simple d-VMAT-based SBRT technique, and it could potentially reduce multileaf collimator (MLC) interplay effects with less MLC modulation through the target and dosimetric errors from small fields. IMRT-based SBRT planning with modulated single-segment fields was used in this work, and it was proposed in our previous work. The resulting dose distribution may be robust to possible interplay effects that are known from highly modulated IMRT irradiations and high-dose rates in relation to moving targets.

SBRT combined with CFRT has been adopted in treatments of patients with locally advanced cancers. The feasibility of SBRT (total dose 40-60 Gy was used in 4 fractions) followed by CFRT (total dose 66 Gy was adopted in 30 fractions for NSCLC and 52.5 Gy in 25 fractions was used for small cell lung cancer) has been evaluated for patients with stage III lung cancer by a prospective single-institution study. About 76% crude LCR was achieved during a 5-year follow up, which was higher than our calculated result (67.3%) by C & S hybrid planning with a similar dose regime to PT combined with a lower dose regime to LNs (total of 60 Gy, 2 Gy/fraction).

Another prospective study evaluated the treatment response by SBRT boost in both residual lung and LNs disease after concomitant chemoradiotherapy for unresectable stage III NSCLC. The rate of local-regional control at 3 years was 59% with a cumulative BED 112.3 Gy to residual lung and LNs disease. More trials are needed to make clear whether implementation of SBRT to both residual lung lesions and LNs decreases the risk of nodal in-field recurrences compared to SBRT to PT followed by CFRT to LNs.

As the interaction effect was reduced by C & SIB planning compared to C & S planning, the physical plan parameter of PTVLN CI benefited from C & SIB planning (0.56 ± 0.12) compared to C & S planning (0.52 ± 0.11) (p = .004).

Table 4. QA Results of the Hybrid Plan Components.

|                    | SBRT plans | CFRT plans | SIB plans |
|--------------------|------------|------------|-----------|
| % (γ<1)            | 97.9 (96.2-99.2) | 97.5 (89.6-100) | 99.4 (97.6-100) |
| γmean              | 0.29 (0.23-0.39) | 0.31 (0.22-0.46) | 0.16 (0.14-0.21) |
| % (Area dose diff <3%) | 74.4 (22.6-90.8) | 78.7 (23.1-91.3) | 94.5 (91.5-97.6) |
| ΔD_{isc} (%)       | −2.1 (−6.9 to −0.2) | −1.7 (−8.5 to 6.5) | −1.6 (−3.9 to 0.1) |

Abbreviations: QA, quality assurance; SBRT, stereotactic body radiotherapy; CFRT, conventional fraction radiotherapy; SIB, simultaneous integrated boost.

Figure 7. Dose difference map of composite beams of one patient’s hybrid plan components (SBRT plan [a], CFRT plan [b], and SIB plan [c]) in nontransit portal dosimetry measurements.

Abbreviations: SBRT, stereotactic body radiotherapy; CFRT, conventional fraction radiotherapy; SIB, simultaneous integrated boost.
Although there was no statistical difference between C & SIB planning and C & S planning for the BED plan parameters such as \( PT_{\text{V,LN}} \text{ CI} \), which may be justified by BED recalculation (a non-linear BED model).32 BED plan parameters of \( PT_{\text{V,LN}} \text{ D}_2 \) and HI were significantly lower by C & SIB planning, resulting that averaged LNs/total TCP curves were slightly lower as a function of TCD$_{50}$ by C & SIB planning, meanwhile, the robustness of LNs/total TCPs has improved with closer Max/Min TCP curves by C & SIB planning.

The incidence rate of grade $\geq 3$ acute radiation pneumonitis (RP) for patients who received SBRT boost before/after chemoradiation in lung cancers were, respectively, 21% (4 of 21) by Yeon et al.$^{16}$ 11.4% (4 of 35) by Feddock et al.$^4$ while the incidence rate of grade $\geq 2$ acute RP was 25% (4 of 16) by Karam et al.$^7$ Our calculated lung NTCP values, $9.1 \pm 4.4\%$ for C & S plans and $9.3 \pm 5.2\%$ for C & SIB plans, were similar to, even less than the RP possibilities from the above 3 results, which may be due to the reason that dose regimes used in above studies were different, meanwhile, patients characteristics, such as age in years and smoking history, are predictive factors for RP.$^{44,45}$ and there may be some differences in the patient characteristics between the studies.

Lung constraints in this work included MLD $<20$ Gy, V5 $<60\%$, and V20 $<30\%$. The relevance of lung volume dose with the rate of RP grade $\geq 3$ was evaluated by a study,$^{45}$ indicating that the rate of RP grade $\geq 3$ was only $2\%$ when the lung dose threshold was met, defined by V50 $\leq 10\%$, V35 $\leq 15\%$, V25 $\leq 20\%$, and V20 $\leq 25\%$. Stricter lung constraints are therefore needed for active smoking and/or old-aged patients, and those with poor lung function.

Compared to our calculated median esophagus NTCP of 45.8% by C & S planning, similar acute esophagitis (9 of 21, 42.9%) was observed by Yeon et al.$^{16}$ with a slightly higher dose regime than LNs. A higher possibility of Grade 1 or 2 radiation esophagitis (11 of 15, 73.3%) was reported by Higgins et al.$^6$ which indicated that more trials are needed to make clear whether implementation of SBRT to both residual lung and LNs disease decreases the risk of nodal in-field recurrences, while improves the risk of acute esophagitis with a low grade. In this work, BED plan parameters of esophagus V$_{50}$ and D$_{\text{max}}$ of C & SIB plans were lower than those of C & S plans, and a significantly lower calculated esophagus NTCP was observed by C & SIB planning. A puzzling problem has arisen that as the esophagus is an early response tissue, a lower esophagus NTCP achieved by C & SIB planning may be compromised by nearly 1 week shorter OTT by C & SIB irradiation compared to C & S irradiation.

There was little follow-up data on the risk of pericarditis and myelitis from stage III lung cancer patients treated by hybrid planning, except the result from Feddock et al.$^4$ that no patients with pericarditis were observed. In this study, although the probabilities of pericarditis and myelitis calculated based on NTCP models were very low, we still need to be cautious about the individual risk of stage III NSCLC patients.

TCP/NTCP of stage III NSCLC is a hybrid planning method, dose regime, and TCD$_{50}$/TD$_{50}$ specific. At present, the dose regime of lung SBRT has been chosen mainly according to AAPM/RTOG reports.$^{46-50}$ Individual dose regime for SBRT treatment has still been a challenge. Meanwhile, similar to TD$_{50}$, the radiation dose needed to control 50% of tumor (TCD$_{50}$) is different among individuals.$^{27,28}$ due to the difference in radiosensitivity between tumor individuals. In this work, It is investigated that tumors with different TCD$_{50}$ levels could obtain different TCPs under the same irradiation level. This work provides a preliminary exploration of the process of taking TCD$_{50}$/TD$_{50}$ as a variable in a TCP/NTCP-objective optimization, but it still depends on a deeper understanding of the radiobiological behavior of tumors and OARs. In the context of reliable TCP/NTCP models and correct TCD$_{50}$/TD$_{50}$ values, this work has the potential to be used to optimize the selection of the hybrid planning method and dose regime for stage III NSCLC in a TCP/NTCP-objective optimization.

EPID dosimetry has been widely used in the pretreatment dose verification of CFRT and SBRT.$^{51,52}$ In this study, non-transit EPID dosimetry was used to verify the components involved in the 2 kinds of hybrid plans, and the results passed the criteria of our center. The average passing rate percentage ($\geq 6\%$) was higher than 97.5%, the average of $\gamma$$_{\text{mean}}$ was $<0.31$, and the mean value of $\Delta D_{\text{iso}}$ (%) was no more than 2.1% for all the components. No patient positioning and anatomical errors in non-transit EPID dosimetry dose verification may result in good pass rates, and they were generally better than the transit results.$^{52}$ As the measured dose image of the SIB plan included 2 areas in imaging: PTV$_{\text{PT}}$-related high-dose area and PTV$_{\text{LN}}$-related low-dose area, we set the dose threshold as 2% to include the low-dose area in the analysis range. Since the global maximum dose normalization method is adopted in the calculation of gamma value, most gamma values in the low-dose area of SIB plans are $<1$, which makes them the highest passing rates among the components of hybrid plans (99.4% [97.6\%-100\%]).

The study presented is a retrospective planning study over 20 patients whose PT is located inside the lung PTV$_{\text{PT}}$, and PET-positive LNs located in the mediastinal area are defined as PTV$_{\text{LN}}$. The hybrid plans require that PTV$_{\text{PT}}$ and PTV$_{\text{LN}}$ are relatively small in volume and spatially separated from each other, only approximately 5%-10% of patients are suitable for hybrid planning. This significantly limits the number of stage III NSCLC as candidates for the presented hybrid plans, and the number would likely increase in the case of an SBRT dose regime with more fractions. This work remains a retrospective comparative planning study. Meanwhile, it is still not clear about individual TCD$_{50}$ values for the specific lung cancer patients, and a reliable TCP/NTCP calculation model suitable for patients treated by hybrid radiotherapy have not yet been established.

In conclusion, CFRT & SIB planning has more advantages on BED plan parameters and TCP/NTCP than CFRT & SBRT planning. Both methods of IMRT-based hybrid planning could be executed accurately for stage III NSCLC. The effectiveness of the results needs to be validated in the hybrid trial.
Authors’ Contributions
HW and YKZ: data collection, statistical analysis, writing, and revising
the manuscript. YH, HC, YS, YHD, AHF, HLG, and XRM: statistical
analysis and revising the manuscript. QK and XZY: study design and
critical revision of the manuscript. All authors gave final approval for
the version to be published.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article. This work was
supported by the Zhongshan Hospital, Fudan University, Shanghai,
China (grant number 2021ZSQN25).

Ethical Approval and Consent to Participate
Project name: Promotion and management of stereotactic radiotherapy
for lung cancer based on the internet. The study is a retrospective study.
When the study began, all selected patients signed informed consent
and completed radiotherapy. Ethical standards and patients’ confidence-
tiality were ensured and in line with regulations of the local institutional
review board and data safety laws. This study was approved by the Ethics Committee of Shanghai Chest Hospital (the committee’s reference Number: KS1863).

Consent for Publication
Not applicable.

Availability of Supporting Data
The datasets used and/or analyzed during the current study are avail-
able from the corresponding author on reasonable request.

ORCID iD
Hao Wang https://orcid.org/0000-0002-7984-6054

References
1. Curran Jr WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-s small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):145-160.
2. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-s small-cell lung cancer: Groupe Lyon-Saint-Étienne d’Oncologie Thoracique-Groupe Français de PneumoCancerologie NPC 95-01 study. J Clin Oncol. 2005;23(25):5910-5917.
3. Huber RM, Flentje M, Schmidt M, et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-s small-cell lung cancer: study CTRT99/97 by the bronchial carcinoma therapy group. J Clin Oncol. 2006;24(27):4397-4404.
4. Feddock J, Arnold SM, Shelton BJ, et al. Stereotactic body radia-
tion therapy can be used safely to boost residual disease in locally
advanced non-s small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2013;85(5):1325-1331.
5. Hepel JT, Leonard KL, Safran H, et al. Stereotactic body radiation
therapy boost after concurrent chemoradiation for locally advanced non-s small cell lung cancer: a phase 1 dose escalation study. Int J Radiat Oncol Biol Phys. 2016;96(5):1021-1027.
6. Higgins KA, Pillai RN, Chen Z, et al. Concomitant chemother-
apy and radiotherapy with SBRT boost for unresectable stage III non-s small-cell lung cancer: a phase 1 study. J Thorac Oncol. 2017;12(11):1687-1695.
7. Karam SD, Horne ZD, Hong RL, McRae D, Duhamel D, Nasr NM. Dose escalation with stereotactic body radiation therapy boost for locally advanced non s small cell lung cancer. Radiat Oncol. 2013;8(1):179.
8. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-199.
9. Lindberg K, Bergstrom P, Brustugun OT, et al. The Nordic HILLUS-trial first report of a phase II trial of SBRT of centrally located lung tumors. Oral Presentation at WCLC. 2016;2016: ID6140,10. Tekatli H, Haasbeek N, Dahele M, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “ultracentral” non-s small cell lung cancer. J Thorac Oncol. 2016;11(7):1081-1089.
10. Tekatli H, Haasbeek N, Dahele M, De Haan P, Verbakel W, Bongers E, et al. Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “ultracentral” non-s small cell lung cancer. J Thorac Oncol. 2016;11:1081-1089.
11. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotac-
tic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833-4839.
12. Hess RT, Sun Y, Matuszak MM, et al. Cardiac events after radia-
tion therapy: combined analysis of prospective multicenter trials for locally advanced non-s small-cell lung cancer. J Clin Oncol. 2017;35(13):1395-1402.
13. Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radio-
therapy for stage III non-s small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35(13):1387-1394.
14. van Diessen JN, Chen C, van den Heuvel MM, Belderbos JS, Sonke JJ. Differential analysis of local and regional failure in locally advanced non-s small cell lung cancer patients treated with concurrent chemoradiotherapy. Radiother Oncol. 2016;118(3):447-452.
15. Schytte T, Nielsen TB, Brink C, Hansen O. Pattern of loco-regional failure after definitive radiotherapy for non-s small cell lung cancer. Acta Oncol. 2014;53(3):336-341.
16. Yeon J K, Su S K, Si Y S, Eun K C. Feasibility of stereotactic radio-
therapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies. Radiat Oncol. 2018;13(1):127.
17. Peulen H, Franssen G, Belderbos J, et al. SBRT combined with concurrent chemoradiation in stage III NSCLC: feasibility study of the phase I hybrid trial. Radiother Oncol. 2020;142:224-229.
22. Niemierko A, Goitein M. Implementation of a model for estimation of equivalent uniform dose (EUD).

23. Bentzen SM, Thames HD. Tumor volume and local control probability for heterogeneous tumor ensembles: data analysis and parameter estimation using a closed-form expression. *Phys Med Biol.* 1998;43(8):2159-2178.

24. Niemierko A. A generalized concept of equivalent uniform dose (EUD). *Med Phys.* 1999;26:1100.

25. Niemierko A. A unified model of tissue response to radiation. In: Proceedings of the 41th AAPM annual meeting; 1999. Med Phys Nashville, Tennesee: p. 1100.

26. Gay HA, Niemierko A. A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. *Phys Med.* 2007;23(3-4):115-125.

27. Mehta N, King CR, Agazaryan N, Steinberg M, Hua A, Lee P. Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control. *Pract Radiat Oncol.* 2012;2(4):288-295.

28. Wulf J, Baier K, Mueller G, Flentje MP. Dose-response in stereotactic irradiation of lung tumors. *Radiother Oncol.* 2005;77(1):83-87.

29. Thieke C, Borstfeld T, Niemierko A, Nill S. From physical dose constraints to equivalent uniform dose constraints in inverse radiotherapy planning. *Med Phys.* 2003;30(9):2332-2339.

30. Wang H, Chen H, Gu HL, et al. A novel IMRT planning study by using the fixed-jaw method in the treatment of peripheral lung cancer with mediastinal lymph node metastasis. *Med Dosim* 2018;43(1):46–54.

31. Haasbeek CJA, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereactic radiotherapy. *Cancer.* 2010;116(2):406-414.

32. Duan YH, Zhou LJ, Wang H, et al. A novel CRT-IMRT-combined (Co-CRIM) planning technique for peripheral lung stereotactic body radiotherapy in pinnacle treatment planning system. *J Appl Clin Med Phys.* 2021;22(12):97-107.

33. Steel GG. Basic Clinical Radiobiology. 3rd ed. Oxford University Press; 2002, 120-146.

34. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. *Int J Radiat Oncol Biol Phys.* 2008;70(3):847-852.

35. Huang BT, Lu JY, Lin PX, Chen JZ, Li DR, Chen CZ. Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy. *Sci Rep.* 2016;6(1):18010.

36. Mohan R, Mageras GS, Baldwin B, et al. Clinically relevant optimization of 3-D conformal treatments. *Med Phys.* 1992;19(4):933-944.

37. Semenenko VA, Li XA. Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. *Phys Med Biol.* 2008;53(3):737-755.

38. Martel MK, Sahijdak WM, Haken RK, Kessler ML, Turrisi AT. Fraction size and dose parameters related to the incidence of pericardial effusions. *Int J Radiat Oncol Biol Phys.* 1998;40(1):155-161.

39. Chapet O, Kong FM, Lee JS, Hayman JA, Haken RK. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiotherapy for non-small cell lung cancer. *Radiother Oncol.* 2005;77(2):176-181.

40. Luo JD, Ma CD, Yu S, Li Z, Ma C. Study of the cumulative dose between fractions of lung cancer radiotherapy based on CT and CBCT image deformable registration technology. *Front Phys.* 2020;40(1):155-161.

41. Wang H, Zhou YK, Gan WT, Chen H, Huang Y, Duan YH, et al. Regression models for predicting physical and EQD2 plan parameters of two methods of hybrid planning for stage III NSCLC. *Radiat Oncol.* 2021;16(1):119.

42. Jens F, Jürgen H, Frederik W, Frank L. Robustness of sweeping-window arc therapy treatment sequences against intrafractional tumor motion. *Med Phys.* 2015;42(4):1538-1545.

43. Damodar P, Justin V, Lana S. A novel and clinically useful dynamic conformal arc (DCA)-based VMAT planning technique for lung SBRT. *J Appl Clin Med Phys.* 2020;21(7):29-38.

44. Takeda A, Kunieda E, Ohashi T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. *Chest.* 2012;141(4):858-866.

45. Jin H, Tucker SL, Liu HH, et al. Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy. *Radiother Oncol.* 2009;91(3):427-432.

46. Benedict SH, Venice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM task group 101. *Med Phys.* 2010;37(8):4078-4101.

47. Guerrero T. A phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I/II non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2015;40:155-161.

48. Timmerman RD, Paulus R, Pass HI, et al. RTOG 0618: stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients[J]. *J Clin Oncol.* 2013;31(4):1263-1266.

49. Bezjak A, Paulus R, Gaspar LE, et al. Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial. *J Clin Oncol.* 2019;37(15):1316-1325.

50. Vidalic GM, Paulus R, Singh AK, et al. Long-term follow-up on NRG oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2019;103(5):1077-1084.
51. Consorti R, Fidanzio A, Brainovich V, et al. EPID-based in vivo dosimetry for stereotactic body radiotherapy of nonsmall cell lung tumors: initial clinical experience. *Phys Medica*. 2017;42:157-161.

52. Olaciregui-Ruiz I, Vivas-Maiques B, Kaas J, et al. Transit and non-transit 3D EPID dosimetry versus detector arrays for patient specific QA. *J Appl Clin Med Phys*. 2019;20(6):79-90.